Methylene blue‐photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study
Open Access
- 5 September 2008
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 143 (1), 39-45
- https://doi.org/10.1111/j.1365-2141.2008.07292.x
Abstract
Plasma exchange (PE) with plasma infusion is the treatment of choice for thrombotic thrombocytopenic purpura (TTP) but doubts remain as to whether all kinds of plasma are equally effective. A multicentric cohort study was conducted to compare methylene blue‐photoinactivated plasma (MBPIP) with quarantine fresh frozen plasma (qFFP) in the treatment of TTP. One hundred and two episodes of idiopathic TTP were included; MBPIP was used in 63 and qFFP in 39. The treatment schedule consisted of daily PE and costicosteroids, and the main end‐point was remission status on day 8. Patients treated with MBPIP required more PEs (median: 11 vs. 5, P = 0·002) and a larger volume of plasma (median: 485 ml/kg vs. 216 ml/kg, P = 0·007) to achieve a remission, and presented more recrudescences while on PE therapy (29 of 63 vs. 8 of 39, P = 0·02) than those receiving qFFP. After adjustment for possible confounding factors, the use of MBPIP was associated with a lower likelihood of remission on day 8 [Odds ratio (OR): 0·17; 95% confidence interval (CI): 0·06–0·47] and a higher risk of recrudescence while on treatment (OR: 4·2; 95% CI: 1·6–10·8). In conclusion, MBPIP is less effective than qFFP in the treatment of TTP.Keywords
This publication has 31 references indexed in Scilit:
- Solvent/detergent-treated plasma: composition, efficacy, and safetyCurrent Opinion in Hematology, 2004
- Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal InvolvementMedicine, 2004
- Methylene blue‐photoinactivated plasma vs. fresh‐frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpuraVox Sanguinis, 2004
- Von Willebrand factor–cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpuraBlood, 2002
- Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWFThrombosis and Haemostasis, 1999
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen-fibrin conversionCellular and Molecular Life Sciences, 1997
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1991
- Equipoise and the Ethics of Clinical ResearchNew England Journal of Medicine, 1987
- Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerizationBiochimica et Biophysica Acta (BBA) - Protein Structure, 1978